secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001140361-23-029970
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys appoints Kendall and Milnes to board, replacing Dyett and Adams
-----------------------------------------------------------------------

- John Dyett and John Adams resigned from board effective June 14, 2023; no disagreement with company.
- Keith Kendall (former CEO/President/CFO of Aquestive Therapeutics) appointed Class III director and Audit Committee Chair.
- Alistair Milnes (COO of Bicycle Therapeutics) appointed Class I director, serves on Audit and Nominating Committees.
- Anne Morrisey resigned from Audit Committee effective June 14, 2023.
- New directors entitled to standard annual retainer and equity awards under company policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123029970/0001140361-23-029970-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123029970/brhc20054453_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-029970

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer